Compare DECK & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DECK | WST |
|---|---|---|
| Founded | 1973 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9B | 17.9B |
| IPO Year | 1996 | 2004 |
| Metric | DECK | WST |
|---|---|---|
| Price | $100.74 | $235.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 7 |
| Target Price | $122.20 | ★ $319.43 |
| AVG Volume (30 Days) | ★ 1.8M | 778.6K |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 0.38% |
| EPS Growth | N/A | ★ 1.49 |
| EPS | 6.04 | ★ 6.79 |
| Revenue | ★ $4,985,612,000.00 | $2,886,900,000.00 |
| Revenue This Year | $11.16 | $6.73 |
| Revenue Next Year | $7.00 | $6.07 |
| P/E Ratio | ★ $16.65 | $34.07 |
| Revenue Growth | ★ 16.28 | 1.95 |
| 52 Week Low | $78.91 | $187.43 |
| 52 Week High | $131.58 | $322.34 |
| Indicator | DECK | WST |
|---|---|---|
| Relative Strength Index (RSI) | 32.43 | 42.34 |
| Support Level | $100.80 | $225.66 |
| Resistance Level | $104.62 | $251.73 |
| Average True Range (ATR) | 3.13 | 6.49 |
| MACD | -1.97 | -1.16 |
| Stochastic Oscillator | 2.53 | 21.27 |
Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2025, Ugg and Hoka accounted for 51% and 45% of total sales, respectively. The firm also markets a niche sandal brand called Teva. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and has more than 200 company-operated stores. It generated 64% of its fiscal 2025 sales in the United States.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.